Processa Pharmaceuticals (PCSA) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic overview and transaction details

• Completed a stock-for-stock acquisition, integrating a lead BTK inhibitor program into the pipeline.

• Secured $200 million in private placement financing, funding operations into the second half of 2029 and supporting multiple clinical milestones.

• Shareholder vote to convert preferred stock to common stock is anticipated in Q4 2026.

• Focused on advancing VT-7208, a differentiated, once-daily oral BTK inhibitor, across multiple indications.

Clinical development plans and timelines

• Advancing VT-7208 into phase II proof-of-concept studies for food allergy, CSU, and relapsing MS, with initial data expected in 2027 and 2028.

• Food allergy and CSU trials to start in the second half of 2026, with readouts in late 2027 and early 2028, respectively.

• Relapsing MS study to begin in early 2027, including progressive MS patients, with data in late 2028.

• Parallel development enables validation across multiple indications and potential expansion into additional diseases.

Market opportunity and scientific rationale

• BTK is a validated target in immunology, with regulatory approvals and proof of concept in at least 10 non-oncology indications.

• Significant unmet need exists in CSU, food allergy, and MS, with millions of patients lacking effective therapies.

• VT-7208 aims to deliver best-in-class efficacy, safety, and convenience, avoiding liver and bleeding risks seen in earlier BTK inhibitors.

• Designed for once-daily low-dose oral administration, targeting both peripheral and CNS diseases.